Key result
Add-on pravastatin enhances vascular endothelial and remodeling improvements from olmesartan in hypertensive rats.
Why the study?
The comparative effects of AT1 receptor blocker, statin, and their combination on vascular injury in salt-sensitive hypertension were not fully understood.
Does the combination of olmesartan and pravastatin improve vascular injury in salt-sensitive hypertensive rats?
Does the combination of olmesartan and pravastatin improve vascular injury in salt-sensitive hypertensive rats?
The combination of an ARB (olmesartan) and a statin (pravastatin) exerts additive beneficial effects on vascular injury and endothelial dysfunction in a rat model of salt-sensitive hypertension.
Answers are grounded in this paper and cite their sources.
Adds preclinical support for ARB-statin synergy on vascular injury; leaves open translation to human hypertension.
Objective—This work was undertaken to investigate comparative effect of AT1 receptor blocker (ARB), 3-hydroxy-3-methylglutaryl (HMG) coenzymeA (CoA) reductase inhibitor (statin), and their combination on vascular injury of salt-sensitive hypertension.Methods and Results—Salt-loaded Dahl salt-sensitive hypertensive rats (DS rats) were treated with (1) vehicle, (2) hydralazine (5 mg/kg/d), (3) olmesartan (0.5 mg/kg/d), (4) pravastatin (100 mg/kg/d), and (5) combined olmesartan and pravastatin for 4 weeks. Olmesartan or pravastatin significantly and comparably improved vascular endothelium-dependent relaxation to acetylcholine, coronary arterial remodeling, and eNOS activity of DS rats. Olmesartan prevented vascular eNOS dimer disruption or the downregulation of dihydrofolate reductase (DHFR) more than pravastatin, whereas Akt phosphorylation was enhanced by pravastatin but not olmesartan, indicating differential pleiotropic effects between olmesartan and pravastatin. Add-on pravastatin significantly enhanced the improvement of vascular endothelial dysfunction and remodeling by olmesartan in DS rats. Moreover, pravastatin enhanced the increase in eNOS activity by olmesartan, being associated with additive effects of pravastatin on phosphorylation of Akt and eNOS.Conclusions—Olmesartan and pravastatin exerted beneficial vascular effects in salt-sensitive hypertension, via differential pleiotropic effects. Pravastatin enhanced vascular protective effects of olmesartan. Thus, the combination of ARB with statin may be the potential therapeutic strategy for vascular diseases of salt-sensitive hypertension.
No takes yet. Share an insight, caveat, or question.
Yamamoto et al. (2006) studied Salt-sensitive hypertension. Combined olmesartan and pravastatin vs. Vehicle, hydralazine, or monotherapies was evaluated on Vascular endothelium-dependent relaxation to acetylcholine, coronary arterial remodeling, and eNOS activity. Add-on pravastatin significantly enhanced the improvement of vascular endothelial dysfunction and remodeling by olmesartan in salt-sensitive hypertensive rats.
Synapse has enriched 10 related papers. Consider them for comparative context: